American Century Companies’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

American Century Companies’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-18,904	Closed	-$1.84M	–	1499
2015 Q1	$1.84M	Sell	18,904 -109	-0.6%	-$11.5K	﹤0.01%	1061
2014 Q4	$1.76M	Sell	19,013 -443	-2%	-$35K	﹤0.01%	1107
2014 Q3	$1.34M	Buy	19,456 +754	+4%	+$54K	﹤0.01%	1128
2014 Q2	$1.96M	Buy	18,702 +1,862	+11%	+$158K	﹤0.01%	1104
2014 Q1	$1.4M	Sell	16,840 -1,160	-6%	-$107K	﹤0.01%	1163
2013 Q4	$1.17M	Sell	18,000 -80	-0.4%	-$4.75K	﹤0.01%	1210
2013 Q3	$1.15M	Buy	18,080 +1,110	+7%	+$54.6K	﹤0.01%	1196
2013 Q2	$729K	Buy	+16,970	New	+$773K	﹤0.01%	1275

American Century Companies's GEVA Position: Q2 2015 in Review

American Century Companies sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 18,904 shares — an estimated $1.84M sold.

American Century Companies first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $1.96M in Q2 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

American Century Companies reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
American Century Companies sold 18,904 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $1.84M.
American Century Companies first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
American Century Companies's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $1.96M in Q2 2014.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on American Century Companies's 13F filing for Q2 2015, filed 28 Jul 2015.